- A novel anthracycline believed to be effective in combatting deadly glioblastoma brain cancers by crossing the blood-brain barrier and zeroing in on the tumor will begin Phase 2 trials during Q1 of next year
- The drug, Berubicin, is being developed by CNS Pharmaceuticals after initial testing nearly 15 years ago resulted in improvements among some subjects, including one who has survived cancer-free since that time
- The company, in collaboration with Polish sub-licensee partner WPD Pharmaceuticals, plans a multinational staged series of trials that will attempt to keep time and costs to outcome at a minimum
- As part of the effort, CNS and WPD plan to conduct the first-ever pediatric Phase 1 trial of Berubicin in children with no other recourse
Brain cancers that are relentless and effectively incurable have caught the attention of drug maker CNS Pharmaceuticals (NASDAQ: CNSP), which is working to complete testing of its lead candidate in hopes of finding a cure against those central nervous system disorders.
The drug, Berubicin, is an anthracycline with the novel distinction of being able to cross the blood-brain barrier to combat tumors — something all other anthracyclines are unable to do. Nearly 15 years ago, Berubicin was the subject of a Phase 1 safety trial conducted by Reata Pharmaceuticals. The limited study resulted not only in a…
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]
BioMedWire is part of the InvestorBrandNetwork.